| Title： | 2023 Fondaparinux Pharmaceutical Practice Guideline |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Medicine and clinical pharmacy |
| Evidence classification method： | GRADE classification system |
| Development unit： | Clinical Pharmacy Branch of Chinese Medical Association；Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital |
| Registration time: | 2023-12-13 |
| Registration number： | PREPARE-2022CN750 |
| Purpose of the guideline: | Thromboembolic disease is a kind of disease with high mortality and serious harm to human health. Anticoagulant therapy is the main treatment for thromboembolic disease. As a parenteral anticoagulant, fondaparinux sodium has caused many problems for medical workers due to the differences in indications at home and abroad and the lack of understanding of its application. There are irrational drug use and drug use beyond the instructions in clinical practice. Therefore, it is particularly important to strengthen the rational use of fondaparinux sodium. |
